<?xml version="1.0" encoding="UTF-8"?>
<ref id="B126-vaccines-07-00053">
 <label>126.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jacobson</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Kuritzkes</surname>
    <given-names>D.R.</given-names>
   </name>
   <name>
    <surname>Godofsky</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>DeJesus</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Larson</surname>
    <given-names>J.A.</given-names>
   </name>
   <name>
    <surname>Weinheimer</surname>
    <given-names>S.P.</given-names>
   </name>
   <name>
    <surname>Lewis</surname>
    <given-names>S.T.</given-names>
   </name>
  </person-group>
  <article-title>Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2009</year>
  <volume>53</volume>
  <fpage>450</fpage>
  <lpage>457</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.00942-08</pub-id>
  <?supplied-pmid 19015347?>
  <pub-id pub-id-type="pmid">19015347</pub-id>
 </element-citation>
</ref>
